The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression

Immunity

Volumn 47, Issue 2, 2017, Pages 284-297.e5

  Pan, Wen ^a,b   Zhu, Shu ^a,c   Qu, Kun ^c   Meeth, Katrina ^a   Cheng, Jijun ^a,b   He, Kaixin ^c   Ma, Hongdi ^c   Liao, Yan ^d   Wen, Xizhi ^e   Roden, Christine ^a,b   Tobiasova, Zuzana ^a   Wei, Zheng ^a   Zhao, Jun ^a   Liu, Jun ^a,b   Zheng, Ji ^a,b,f   Guo, Bo ^a,g   Khan, Sajid A ^a   Bosenberg, Marcus ^a   Flavell, Richard A ^a   Lu, Jun ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^d SUN YAT SEN UNIVERSITY   (China)

^e SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^f THIRD MILITARY MEDICAL UNIVERSITY   (China)

^g CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

5hmC; 5mC; Arg1; BMDM; HSC; Il1b; MDSC; TAM; Tet3; YUMM1.7

Indexed keywords

DNA BINDING PROTEIN; ONCOPROTEIN; TET2 PROTEIN, HUMAN; TET2 PROTEIN, MOUSE;

ANIMAL; C57BL MOUSE; CARCINOGENESIS; EXPERIMENTAL MELANOMA; FEMALE; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; MALE; MELANOMA; METABOLISM; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; SKIN TUMOR; T LYMPHOCYTE; TUMOR ESCAPE; TUMOR VOLUME;

ANIMALS; CARCINOGENESIS; DNA-BINDING PROTEINS; FEMALE; HUMANS; MALE; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID-DERIVED SUPPRESSOR CELLS; PROTO-ONCOGENE PROTEINS; SKIN NEOPLASMS; T-LYMPHOCYTES; TUMOR BURDEN; TUMOR ESCAPE;

EID: 85027449995     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2017.07.020     Document Type: Article

References (61)

1. Abram, C.L., Roberge, G.L., Hu, Y., Lowell, C.A., Comparative analysis of the efficiency and specificity of myeloid-Cre deleting strains using ROSA-EYFP reporter mice. J. Immunol. Methods 408 (2014), 89–100.
2. Amit, I., Winter, D.R., Jung, S., The role of the local environment and epigenetics in shaping macrophage identity and their effect on tissue homeostasis. Nat. Immunol. 17 (2016), 18–25.
3. An, J., González-Avalos, E., Chawla, A., Jeong, M., López-Moyado, I.F., Li, W., Goodell, M.A., Chavez, L., Ko, M., Rao, A., Acute loss of TET function results in aggressive myeloid cancer in mice. Nat. Commun., 6, 2015, 10071.
4. Bhatia, S., Thompson, J.A., Melanoma: immune checkpoint blockade story gets better. Lancet 384 (2014), 1078–1079.
5. Biswas, S.K., Sica, A., Lewis, C.E., Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J. Immunol. 180 (2008), 2011–2017.
6. Busque, L., Patel, J.P., Figueroa, M.E., Vasanthakumar, A., Provost, S., Hamilou, Z., Mollica, L., Li, J., Viale, A., Heguy, A., et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat. Genet. 44 (2012), 1179–1181.
7. Callahan, M.K., Immune checkpoint therapy in melanoma. Cancer J. 22 (2016), 73–80.
8. Carmi, Y., Voronov, E., Dotan, S., Lahat, N., Rahat, M.A., Fogel, M., Huszar, M., White, M.R., Dinarello, C.A., Apte, R.N., The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J. Immunol. 183 (2009), 4705–4714.
9. Cataisson, C., Salcedo, R., Hakim, S., Moffitt, B.A., Wright, L., Yi, M., Stephens, R., Dai, R.M., Lyakh, L., Schenten, D., et al. IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesis. J. Exp. Med. 209 (2012), 1689–1702.
10. Chen, Q., Chen, Y., Bian, C., Fujiki, R., Yu, X., TET2 promotes histone O-GlcNAcylation during gene transcription. Nature 493 (2013), 561–564.
11. Chin, L., The genetics of malignant melanoma: lessons from mouse and man. Nat. Rev. Cancer 3 (2003), 559–570.
12. Church, S.E., Galon, J., Tumor microenvironment and immunotherapy: the whole picture is better than a glimpse. Immunity 43 (2015), 631–633.
13. Colegio, O.R., Chu, N.Q., Szabo, A.L., Chu, T., Rhebergen, A.M., Jairam, V., Cyrus, N., Brokowski, C.E., Eisenbarth, S.C., Phillips, G.M., et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513 (2014), 559–563.
14. Cullen, S.M., Goodell, M.A., Dynamic DNA methylation discovered during HSC differentiation. Cell Cycle 14 (2015), 693–694.
15. Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky, W.E. Jr., You, M.J., DePinho, R.A., McMahon, M., Bosenberg, M., Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41 (2009), 544–552.
16. Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002), 949–954.
17. Delhommeau, F., Dupont, S., Della Valle, V., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.P., Robert, F., Alberdi, A., et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360 (2009), 2289–2301.
18. Doedens, A.L., Stockmann, C., Rubinstein, M.P., Liao, D., Zhang, N., DeNardo, D.G., Coussens, L.M., Karin, M., Goldrath, A.W., Johnson, R.S., Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 70 (2010), 7465–7475.
19. Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H.F., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18 (2010), 553–567.
20. Franklin, R.A., Liao, W., Sarkar, A., Kim, M.V., Bivona, M.R., Liu, K., Pamer, E.G., Li, M.O., The cellular and molecular origin of tumor-associated macrophages. Science 344 (2014), 921–925.
21. Genovese, G., Kähler, A.K., Handsaker, R.E., Lindberg, J., Rose, S.A., Bakhoum, S.F., Chambert, K., Mick, E., Neale, B.M., Fromer, M., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371 (2014), 2477–2487.
22. He, Y.F., Li, B.Z., Li, Z., Liu, P., Wang, Y., Tang, Q., Ding, J., Jia, Y., Chen, Z., Li, L., et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333 (2011), 1303–1307.
23. Ho, P.C., Bihuniak, J.D., Macintyre, A.N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.C., Cui, G., Micevic, G., Perales, J.C., et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162 (2015), 1217–1228.
24. Huang, Y., Rao, A., Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet. 30 (2014), 464–474.
25. Ichiyama, K., Chen, T., Wang, X., Yan, X., Kim, B.S., Tanaka, S., Ndiaye-Lobry, D., Deng, Y., Zou, Y., Zheng, P., et al. The methylcytosine dioxygenase Tet2 promotes DNA demethylation and activation of cytokine gene expression in T cells. Immunity 42 (2015), 613–626.
26. Ito, S., Shen, L., Dai, Q., Wu, S.C., Collins, L.B., Swenberg, J.A., He, C., Zhang, Y., Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333 (2011), 1300–1303.
27. Jablonski, K.A., Amici, S.A., Webb, L.M., Ruiz-Rosado, Jde.D., Popovich, P.G., Partida-Sanchez, S., Guerau-de-Arellano, M., Novel markers to delineate murine M1 and M2 macrophages. PLoS ONE, 10, 2015, e0145342.
28. Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P.V., Mar, B.G., Lindsley, R.C., Mermel, C.H., Burtt, N., Chavez, A., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371 (2014), 2488–2498.
29. Ko, M., Huang, Y., Jankowska, A.M., Pape, U.J., Tahiliani, M., Bandukwala, H.S., An, J., Lamperti, E.D., Koh, K.P., Ganetzky, R., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468 (2010), 839–843.
30. Ko, M., Bandukwala, H.S., An, J., Lamperti, E.D., Thompson, E.C., Hastie, R., Tsangaratou, A., Rajewsky, K., Koralov, S.B., Rao, A., Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc. Natl. Acad. Sci. USA 108 (2011), 14566–14571.
31. Langemeijer, S.M., Kuiper, R.P., Berends, M., Knops, R., Aslanyan, M.G., Massop, M., Stevens-Linders, E., van Hoogen, P., van Kessel, A.G., Raymakers, R.A., et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 41 (2009), 838–842.
32. Lewis, A.M., Varghese, S., Xu, H., Alexander, H.R., Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J. Transl. Med., 4, 2006, 48.
33. Li, Z., Cai, X., Cai, C.L., Wang, J., Zhang, W., Petersen, B.E., Yang, F.C., Xu, M., Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118 (2011), 4509–4518.
34. Li, X., Zhang, Q., Ding, Y., Liu, Y., Zhao, D., Zhao, K., Shen, Q., Liu, X., Zhu, X., Li, N., et al. Methyltransferase Dnmt3a upregulates HDAC9 to deacetylate the kinase TBK1 for activation of antiviral innate immunity. Nat. Immunol. 17 (2016), 806–815.
35. Marvel, D., Gabrilovich, D.I., Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J. Clin. Invest. 125 (2015), 3356–3364.
36. Meeth, K., Wang, J.X., Micevic, G., Damsky, W., Bosenberg, M.W., The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell Melanoma Res. 29 (2016), 590–597.
37. Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M.E., Vasanthakumar, A., Patel, J., Zhao, X., et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20 (2011), 11–24.
38. Muzio, M., Ni, J., Feng, P., Dixit, V.M., IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 278 (1997), 1612–1615.
39. Ngiow, S.F., Meeth, K.M., Stannard, K., Barkauskas, D.S., Bollag, G., Bosenberg, M., Smyth, M.J., Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAF(V600E) melanoma. OncoImmunology, 5, 2015, e1089381.
40. Noy, R., Pollard, J.W., Tumor-associated macrophages: from mechanisms to therapy. Immunity 41 (2014), 49–61.
41. Okabe, Y., Medzhitov, R., Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell 157 (2014), 832–844.
42. Ostuni, R., Kratochvill, F., Murray, P.J., Natoli, G., Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol. 36 (2015), 229–239.
43. Pauleau, A.L., Rutschman, R., Lang, R., Pernis, A., Watowich, S.S., Murray, P.J., Enhancer-mediated control of macrophage-specific arginase I expression. J. Immunol. 172 (2004), 7565–7573.
44. Pietras, E.M., Mirantes-Barbeito, C., Fong, S., Loeffler, D., Kovtonyuk, L.V., Zhang, S., Lakshminarasimhan, R., Chin, C.P., Techner, J.M., Will, B., et al. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nat. Cell Biol. 18 (2016), 607–618.
45. Qian, B.Z., Pollard, J.W., Macrophage diversity enhances tumor progression and metastasis. Cell 141 (2010), 39–51.
46. Quivoron, C., Couronné, L., Della Valle, V., Lopez, C.K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.H., et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20 (2011), 25–38.
47. Rawal, S., Park, H.J., Chu, F.L., Zhang, M., Nattamai, D., Kannan, S.C., Sharma, R., Delgado, D.A., Chou, T., Davis, R.E., Neelapu, S.S., Role of IL-4 in inducing immunosuppressive tumor microenvironment in follicular lymphoma. Blood 118 (2011), 349–350.
48. Rodriguez, P.C., Hernandez, C.P., Quiceno, D., Dubinett, S.M., Zabaleta, J., Ochoa, J.B., Gilbert, J., Ochoa, A.C., Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 202 (2005), 931–939.
49. Sharda, D.R., Yu, S., Ray, M., Squadrito, M.L., De Palma, M., Wynn, T.A., Morris, S.M. Jr., Hankey, P.A., Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase. J. Immunol. 187 (2011), 2181–2192.
50. Tahiliani, M., Koh, K.P., Shen, Y., Pastor, W.A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L.M., Liu, D.R., Aravind, L., Rao, A., Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324 (2009), 930–935.
51. Tsagaratou, A., Äijö, T., Lio, C.W., Yue, X., Huang, Y., Jacobsen, S.E., Lähdesmäki, H., Rao, A., Dissecting the dynamic changes of 5-hydroxymethylcytosine in T-cell development and differentiation. Proc. Natl. Acad. Sci. USA 111 (2014), E3306–E3315.
52. Voronov, E., Shouval, D.S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., Dinarello, C.A., Apte, R.N., IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA 100 (2003), 2645–2650.
53. Voronov, E., Carmi, Y., Apte, R.N., The role IL-1 in tumor-mediated angiogenesis. Front. Physiol., 5, 2014, 114.
54. Wesche, H., Henzel, W.J., Shillinglaw, W., Li, S., Cao, Z., MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. Immunity 7 (1997), 837–847.
55. Wu, H., Zhang, Y., Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev. 25 (2011), 2436–2452.
56. Xie, M., Lu, C., Wang, J., McLellan, M.D., Johnson, K.J., Wendl, M.C., McMichael, J.F., Schmidt, H.K., Yellapantula, V., Miller, C.A., et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat. Med. 20 (2014), 1472–1478.
57. Xue, S., Liu, C., Sun, X., Li, W., Zhang, C., Zhou, X., Lu, Y., Xiao, J., Li, C., Xu, X., et al. TET3 inhibits type I IFN production independent of DNA demethylation. Cell Rep. 16 (2016), 1096–1105.
58. Yadav, M., Delamarre, L., IMMUNOTHERAPY. Outsourcing the immune response to cancer. Science 352 (2016), 1275–1276.
59. Yang, R., Qu, C., Zhou, Y., Konkel, J.E., Shi, S., Liu, Y., Chen, C., Liu, S., Liu, D., Chen, Y., et al. Hydrogen sulfide promotes Tet1- and Tet2-mediated Foxp3 demethylation to drive regulatory T cell differentiation and maintain immune homeostasis. Immunity 43 (2015), 251–263.
60. Ye, M., Iwasaki, H., Laiosa, C.V., Stadtfeld, M., Xie, H., Heck, S., Clausen, B., Akashi, K., Graf, T., Hematopoietic stem cells expressing the myeloid lysozyme gene retain long-term, multilineage repopulation potential. Immunity 19 (2003), 689–699.
61. Zhang, Q., Zhao, K., Shen, Q., Han, Y., Gu, Y., Li, X., Zhao, D., Liu, Y., Wang, C., Zhang, X., et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 525 (2015), 389–393.